← Browse by Condition
Medical Condition
refractory cancer
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
NCT06229340 Phase 2
Recruiting
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Enrollment
20 pts
Location
Russia
Sponsor
N.N. Petrov National Medical R...
NCT05359445 Phase 1
Recruiting
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Enrollment
95 pts
Location
Germany
Sponsor
Immatics Biotechnologies GmbH
NCT03686124 Phase 1, Phase 2
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Enrollment
375 pts
Location
United States, Germa...
Sponsor
Immatics US, Inc.